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A dilute-and-shoot flow-injection tandem mass spectrometry
method for quantification of phenobarbital in urine

RATIONALE: Liquid chromatography/tandem mass spectrometry (LC/MS/MS) is the gold standard of urine drug
testing. However, current LC-based methods are time consuming, limiting the throughput of MS-based testing and
increasing the cost. This is particularly problematic for quantification of drugs such as phenobarbital, which is often
analyzed in a separate run because they must be negatively ionized.
METHODS: This study examined the feasibility of using a dilute-and-shoot flow-injection method without LC separation
to quantify drugs with phenobarbital as a model system. Briefly, a urine sample containing phenobarbital was first diluted
by 10 times, followed by flow injection of the diluted sample to mass spectrometer. Quantification and detection of
phenobarbital were achieved by an electrospray negative ionization MS/MS system operated in the multiple reaction
monitoring (MRM) mode with the stable-isotope-labeled drug as internal standard.
RESULTS: The dilute-and-shoot flow-injection method developed was linear with a dynamic range of 50-2000 ng∕mL of
phenobarbital and correlation coefficient > 0.9996. The coefficients of variation and relative errors for intra- and interassays at four quality control (QC) levels (50, 125, 445 and 1600 ng∕mL) were 3.0% and 5.0%, respectively. The total
run time to quantify one sample was 2 min, and the sensitivity and specificity of the method did not deteriorate even after
1200 consecutive injections.
CONCLUSIONS: Our method can accurately and robustly quantify phenobarbital in urine without LC separation. Because
of its 2 min run time, the method can process 720 samples per day. This feasibility study shows that the dilute-and-shoot
flow-injection method can be a general way for fast analysis of drugs in urine. Copyright © 2016 John Wiley & Sons, Ltd.

Pain management drugs are among the most commonly
prescribed drugs and yet also the most abused drugs.[1-4]
Therefore, it has become a general medical practice to monitor
patients who are taking pain management drugs, for
adherence to treatment as well as to detect presence of other
illicit substances and unprescribed drugs. The urine drug test
(UDT) is the current clinical procedure for such patient
monitoring, and there are millions of UDTs performed each
year[5-8] Recently, liquid chromatography/tandem mass
spectrometry (LC/MS/MS) has emerged as the gold standard
UDT for quantification of pain management drugs in urine.
A routine UDT screening panel consists of more than 50
commonly prescribed pain management drugs along with
other abused molecules, among which only ethyl glucuronide
(EtG, a metabolite biomarker for alcohol abuse) and
barbiturates (commonly abused drugs) must be negatively
ionized,[9-15] while the rest of them are positively ionized.
Moreover, although both of them are negatively ionized, they
must be analyzed in different LC runs because EtG is highly
polar, while barbiturates are hydrophobic. Therefore, three
separate LC/MS/MS runs[16-19] are generally carried out to
identify/quantify the whole panel of pain management drugs

and illicit drugs in a routine clinical operation. This means that
a single LC/MS/MS run operated in the positive ionization
mode simultaneously analyzes the overwhelming majority of
the drugs, and two additional separate LC/MS/MS runs are
needed just to analyze EtG and barbiturates. The equipment
needed for LC/MS/MS is expensive, requiring HPLC
separation along with the MS/MS detection of drug molecules.
Compared to MS∕MS, HPLC has a much longer run time to
separate different molecules and reduce interferences,
becoming the bottleneck of LC/MS/MS. Clearly, the general
practice of running two separate LC/MS/MS runs just to
analyze EtG and barbiturates greatly limits the throughput
and increases the cost of a UDT. Hence, increasing the speed
(throughput) of analyzing EtG and barbiturates is a major
challenge faced by the clinical chemistry community.
As a part of our comprehensive effort to develop simple and
rapid MS/MS-based methods for quantification of biomarkers
in clinical specimens, we examined the feasibility of using the
dilute-and-shoot flow-injection MS/MS (FI-MS/MS) method
(without LC separation) for urine drug testing. In our method,
a urine sample containing target drugs is spiked with internal
standards, followed by enzymatic hydrolysis to cleave
glucuronide conjugates.'20-22' The enzymatic treated sample
is then diluted to minimize the matrix effect. Thereafter, the
diluted sample is directly injected into the electrospray
ionization (ESI) source of a tandem mass spectrometer
operated in a MRM mode for identification and quantification.
We hypotheses that this simple dilution along with selecting

good internal standards allows for fast, accurate and robust
quantification of drugs in urine without pre-purification and
LC separation.
In this study, we employed phenobarbital, the most
prescribed barbiturate, as the model system to demonstrate
the proof of principle. It was found that the dilute-shoot FIMS/MS method developed was fast and robust for accurate
quantification of phenobarbital in urine, where an
autosampler directly introduces the sample along with the
solvent into the mass spectrometer without a chromatographic
column. The run time of our method is only 2 min long,
enabling analysis of more than 720 urine samples per day,
substantially increasing the throughput of MS-based UDT
methods. To the best of our knowledge, this is the first report
of accurate quantification of phenobarbital in urine by MS/MS
without both pre-purification and LC separation. Reporting
this study constitutes the focus of our communication.

EXPERIMENTAL
Materials and methods
Phenobarbital (analyte) and phenobarbital-D5 (internal
standard, IS) were purchased from Cerilliant Corporation
(Round Rock, TX, USA). B-Glucurodinase, Type-1, was
obtained from Helix pomatia, and ammonium acetate were
purchased from Sigma-Aldrich (Allentown, PA, USA). HPLC
grade methanol and acetonitrile were purchased from
Pharmco-Apper (Philadelphia, PA, USA). Deionized water
was obtained from a Barnstead Nano pure water purification
system from Thermo Scientific (Waltham, MA, USA). Drugfree urine was donated by six different healthy volunteers
and was verified to not contain drugs before analysis.
Sample preparation

The urine drug samples used in this study were prepared by
spiking phenobarbital and phenobarbital-D5 (IS) at the
concentrations of 50, 100, 200, 500, 1000, and 2000 ng/mL
and 500 ng∕mL (IS) respectively, in human blank urine. Each
of the samples (100 μL) was then subjected to enzymatic
hydrolysis by adding 200 units of β-glucurodinase and
3 mM ammonium acetate buffer, vortexed, and then incubated
at 55°C for 2 h. The hydrolyzed urine calibrators were diluted
by ten times with deionized water and centrifuged at 13,000 g
for 20 min. The supernatants were transferred into
autosampler vials and analyzed using FI-MS/MS.

MS/MS instrumentation

Sample analysis was performed using 5500 QTRAP triple
quadrupole mass spectrometer (AB Sciex, Toronto, Canada)
with an electrospray ionization (ESI) source interfaced with
a HPLC system containing two LC-30 AD pumps, a DUG20A3R inline degasser, a SIL-30 AC autosampler, a CBM20 A controller and a CTO-10AVP column oven (Shimadzu,
Columbia, MD, USA).[23-25] It is noted that the HPLC system
used herein was just for How-injecting samples into the ESI
source and has no chromatography column connected.
Ammonium acetate (5 mM) in 70% acetonitrile was employed
as a carrier solvent at a flow rate of 0.3 mL∕min to inject the
sample and the same solvent was used as a wash solvent,

which was done only after injecting samples with the highest
concentration (2000 ng∕mL) in each batch. A volume of 10 μL
of the sample was injected with a run time of 2 min per sample.
All the MS and sample injection parameters were selected and
controlled by Analyst software (version 1.5.2; AB Sciex,
Toronto, Canada).
The ESI source and analyte-dependent MS parameters were
optimized by a direct infusion of phenobarbital at 50 ng ∕mL in
the negative ion mode. The parameters were selected based on
a combination of high ion intensity, low noise background in
urine matrix and reproducible analyte peak intensity. The
MS parameters were as follows: (i) ESI source dependent
parameters were optimized by direct infusion analysis:
Curtain gas (35), nebulization gas (Gas I) (30), heating gas
(Gas II) (30), ion spray voltage (-4000 eV), temperature
(450°C). (ii) Analyte-dependent parameters were fine-tuned
manually as follows: declustering potential (—110), entrance
potential (—15), collision energy (—19), Cell exit potential
(—15), dwell time for each multiple reaction monitoring
(MRM) transition (150 ms).

Preparation of working solutions, calibrators, and quality
control (QC) samples

Separate stock solutions of phenobarbital and phenobarbitalD5 (IS) were prepared at 50 μg∕mL and 10 μg∕mL from
1 mg∕mL and 100 μg∕mL main stock solutions, respectively.
The calibrators and QC samples were prepared from different
sources of stock solutions. A set of phenobarbital working
solutions of 50, 100, 200, 500, 1000, and 2000 ng/mL spiked
with 500 ng∕mL phenobarbital-D5 (IS) were prepared by serial
dilution from the stock solutions of phenobarbital and IS (in
methanol), respectively. Similarly, the pooled urine calibrators
(mixture of 6 lots of blank human urine) were prepared by
spiking phenobarbital at 50-2000 ng/mL and 500 ng/mL IS
followed by enzymatic hydrolysis and simple ten times
(10×) dilution. Accuracy and precision measurements were
assessed in QC samples at 50, 125, 445 and 1600 ng/mL,
representing the lower limit of quantification (LLOQ), low
QC (LQC), mid QC (MQC), and high QC (HQC) urine
solutions, respectively. The working, QC and calibrators were
then subjected to FI-MS/MS analysis. All the concentrations of
phenobarbital reported are equivalent to the concentrations of
phenobarbital in solvent without dilution.

RESULTS AND DISCUSSION
Method development
Optimization offlow injection mass spectrometric conditions for
MRM quantitation
Because the dilute-and-shoot FI-MS/MS system has no LC
column to separate the interfering background from the target
drug and internal standard molecules, we first developed the
conditions to minimize the effect of any potential interfering
background on quantification. This was achieved by
analyzing six different urine samples containing no
phenobarbital under various conditions. Infusion experiments
were performed to optimize MS/MS parameters, to select
carrier solvent, buffers and fragment ions, and to produce
strong signals of both the drug and IS. The negative ESI mode

was selected because phenobarbital is an acidic drug with a
pH of 9-10, which carries a negative charge on the oxygen at
position 4 of the barbiturate ring and thus can be more
efficiently ionized in the negative ion mode. The internal
standard (IS) used in this work was phenobarbital-D5. The
use of deuterated drug molecules as internal standards can
improve the quantitative accuracy, which is essential to
dilute-and-shoot methods.[26-28]

Selection ofMRM transitions - phenobarbital and phenobarbital-D5
(IS) fragmentation

Fragmentation of precursor ions by collision-induced
dissociation (CID), with a collision energy of 20 eV and the
dwell time at 300 ms, led to the identification of product ions,
with the transitions set at m/z 231.1 → 42.1 (quantitative) and
m/z 231.1 → 188.1 (qualitative) for phenobarbital, and m/z
234.2 → 85.1 for the IS (phenobarbital-D5), respectively. The
fragmentation patterns are shown in Fig. 1. Under the
conditions, the signal to noise was high, while the interference
from other molecules was significantly reduced[29] It is noted
that in this study, we have carefully evaluated the transitions
m/z 231.1 → 188.1 and 231.1 → 42.1 in both the method
development and validation phases. The transition m/z
231.1 → 42.1 was selected as the quantitative channel due to
its high signal intensity and better signal-to-noise ratio
compared to m/z 231.1 → 188.1. The transition m/z
231.1 → 188.1 was selected as a confirmation channel because

it is highly specific to phenobarbital. The fragment at m/z 42
(NCO-) was derived via a retro-Diels-Alder reaction in CID,
which is most commonly used for quantification of
barbiturates.'30' The fragment at m/z 188.1 used as a
confirmation channel was obtained by fragmentation at the
N-C bond with a loss of a NCO- moiety. The fragment of m∕
z 85 (ONONH-), which was used as the quantification channel
for the IS, was due to the fragmentation at the negative charge
at O2 or O4 of the phenobarbital-D5 ring (IS). A quantitative
channel is used to calculate the concentration based on the
quantifier ion, while a qualitative channel is used to confirm
the identification of the target analyte based on the ratio of
the qualifier ion to quantifier ion.[27]
After optimization, we found that both the drug
(phenobarbital) and the IS were well differentiated and that
the background interference was minor, allowing for both
the qualitative and quantitative determination of
phenobarbital by MRM operated in the negative ionization
mode. An isocratic flow of carrier solvent, 5 mM ammonium
acetate in 70% acetonitrile at a flow rate of 0.3 mL∕min, was
used to inject samples, as this solvent led to stronger signals
for both phenobarbital and the IS and more effectively
reduced the interference, compared with other solvents and
buffers studied. The run time of our FI-MS/MS method
was set for 2 min for each sample with a 10 μL injection
volume. Under our optimized conditions, the peak with
the strongest phenobarbital and IS signals was at 0.7 min
after injection.

Figure 1. Precursor/product ion spectra and proposed fragmentation
pathways for (A) phenobarbital and (B) internal standard phenobarbital-D5.

Phenobarbital cutoff concentration and calibration curve

In general, different predetermined cutoffs are used for
different drugs, based on their distinct clinical significance.
A too high cutoff can lead to false negatives, while false
positives occur with a too low cutoff.[31,32] Based on clinical
practice, a phenobarbital cutoff is generally set at 200 ng/mL
(200 ng phenobarbital in 1 mL urine) by many reference
laboratories.[27,33-35] With this in mind, we developed our
calibration curve with the phenobarbital concentration
ranging from 50 to 2000 ng/mL (Fig. 2), where the LLOQ
(50 ng/mL) was set at 25% of the cutoff value (200 ng/mL
phenobarbital). It is noted that the concentrations listed are
the concentrations before 10× dilutions. Phenobarbital urine
calibrators were prepared to obtain six urine calibrators:
50 ng/mL, 100 ng/mL, 200 ng/mL (cutoff), 500 ng/mL,
1000 ng∕mL and 2000 ng∕mL, where the cutoff concentration
(200 ng∕mL) in urine falls in the mid-point of our linear range,
enabling our method to determine the concentrations both
higher and lower than the cutoff value in urine samples.
Analytical method validation

A full method validation was performed for precision,
accuracy, selectivity, lower limit of quantification (LLOQ),
matrix effect and sample stability. The entire method was
validated according to the currently accepted FDA
Bioanalytical Method guidelines.[36]
Linearity, selectivity, sensitivity and LLOQ

The calibration plots were established using six phenobarbital
urine calibrators at the concentrations of 50,100,200,500,1000,
and 2000 ng∕mL, double blank and single blank (only IS). An
excellent linearity was achieved with the mean correlation
coefficient of r = 0.9996. Also, the calibration curves were
evaluated by plotting standardized residual plots and checked
for any outliers for each calibrator during the course of method
validation for five batches on five separate days. The standard
deviation (SD) for the residuals was found to be in the range of
0.83-2.02, which is acceptable (< ±3 SD). The LLOQ and

Analyte Conc. I IS
Conc.

Figure 2. Calibration curve of phenobarbital in pooled blank
human urine (mixture of 6 lots, 10× dilution). Linear
regression (l /x weighting): y = 0.146x + —0.0278 (r = 0.9996).

selectivity of the method were assessed using the LLOQ
(50 ng∕mL phenobarbital) and double blank urine samples
from six different urine sources. Phenobarbital (Fig. 3) and IS
peaks (Fig. 4) at LLOQ were obtained at ~0.7 min and no
significant interferences were detected in these time windows
in blank urine samples, showing the high selectivity of our
method. The S/N ratio of the quantitative transition (42.1)
and the qualitative transition (188.1) was 20 and 10 at LLOQ,
respectively (Figs. 3 and 4). The coefficient of variation
(%CV) and accuracy for the LLOQ were 1.4% and 3.5%,
respectively, meeting the requirement of FDA guidelines
(Table 1).

Precision, accuracy and matrix effect

To evaluate intra-day (within the same day) and inter-day (5
different days) precision and accuracy, five replicates of three
QC standards, LQC, MQC, and HQC of 125, 445 and
1600 ng∕mL concentrations, along with the calibrators (502000 ng/mL) were analyzed within the same day and for 5
consecutive days, respectively. The values for intra- and
inter-day precision and accuracies ranged from 2.0 to 2.5%
and 1.0 to 3.0%, and 1.98 to 3.78% and 1.47% to 4.19%,
respectively, indicating that the FI-MS/MS method developed
is highly precise and accurate with negligible deviations
(Table 2).
Absolute and relative matrix effects were investigated in
triplicate at three QC concentrations (125, 445 and
1600 ng∕mL) in both pooled blank urine (mixture of 6 lots)
and six individual urine lots. The absolute matrix effect was
calculated by comparing the peak areas of diluted blank urine
samples (10× dilution, both pooled and individual blank
urine) spiked with phenobarbital at three QC concentrations
with those of corresponding standard solutions at equivalent
concentrations. The relative matrix effect was calculated by
comparing the peak area ratio of phenobarbital and IS
(phenobarbital-D5) spiked in the diluted blank urine samples
at the same three QC concentrations with corresponding
standard solutions at equivalent concentrations. The absolute
matrix effect for each of the three QC pooled urine samples
was 103.8%, 110.8%, and 112.8% and the relative matrix effect
was found to be 98.7%, 108% and 110.5%, respectively
(Table 3).
Similarly, absolute and relative matrix effect studies were
performed in triplicate at three QC concentrations (125, 445
and 1600 ng/mL) with six individual urine lots to determine
the extent of variation of ion suppression among each lot.
The absolute matrix effect for each lot at three QC
concentrations ranged from 102.6 to 113.2% and the relative
matrix effect ranged from 92.1 to 112.4%, respectively. The
variability of the matrix effect among different urine samples
was expressed as percent coefficient variation (%CV), where
acceptable values <12% were obtained. These studies clearly
show that the dilute-and-shoot technique for sample
preparation was effective and had minimal matrix effects.
Sample stability studies
The stability studies (n = 3) were performed using two
different QC standards (125 and 1600 ng/mL), which were
exposed to the following regimens: 6 h at room temperature
(bench-top stability), 2 months at —20oC, and 3 freeze/thaw

Figure 3. MRM extracted ion chromatograms (XICs) of (a) double blank pooled
human urine (mixture of 6 lots, 10× dilution), (b) Blank pooled human urine
(mixture of 6 lots, 10× dilution) spiked with phenobarbital at LLOQ level
(50 ng/mL): Quantitative channel (42.0) and (c) Qualitative channel (188.0).

Figure 4. MRM extracted ion chromatograms (XICs) of (a) double blank pooled
human urine (mixture of 6 lots, 10× dilution) and (b) single blank pooled human
urine (mixture of 6 lots, 10× dilution) spiked with internal standard
(phenobarbital-D5) (500 ng/mL).

cycles within 3 days. The stability of phenobarbital and IS in
human urine was evaluated after each storage period and
compared to the freshly prepared samples of equivalent
concentrations. The drug molecules were found to be stable
and no loss or degradation of the analyte in urine was
observed in all the studies (Table 4).

Interference from other drugs

As described earlier, the current UDT typically detects two
analytes in the negative ion mode. They are barbiturates and
EtG. We have carried out a study to determine the effect of
these molecules on the quantification of phenobarbital in

Table 1. Accuracy and precision of phenobarbital
calibration standards in pooled blank human urine

Table 3. Absolute (AME) and relative matrix effect (RME)
of phenobarbital in pooled blank human urine

Spiked conc.
(ng/mL)

Phenobarbital conc. AME ± SD
RME±SD
(ng/mL)
%CV
%CV
(%)
(%)

50
100
200
500
1000
2000

Determined conc.
(ng/mL)

Accuracy
(%RE)

Precision
(%CV)

51.07 ±0.07
101.02 ± 0.21
190.88 ± 0.48
497.3 ± 0.88
1009.0 ± 1.11
2000.0 ± 0.54

3.50
1.20
4.50
1.27
0.98
0.10

1.4
2.1
2.5
1.8
1.1
0.7

50
125
445
1600

108.5
103.8
110.8
112.8

±
±
±
±

0.33
0.22
1.07
2.56

7
2
2
2

95.3
98.7
108
110.5

±
±
±
±

0.33
0.22
1.07
2.56

6.9
2.1
1.9
2

Mixture of 6 lots, 10× Dilution (n = 3)

Mixture of 6 lots, 10× dilution (n = 5) over 50-2000 ng/mL
Table 4. Sample stability studies of phenobarbital in
pooled blank human urine

urine, where we spiked secobarbital, butalbital, pentobarbital
and EtG into urine samples containing phenobarbital (LLOQ:
50 ng∕mL, LQC: 125 ng∕mL, MQC: 445 ng∕mL, and HQC:
1600 ng∕mL). This test was performed using both six separate
lots of urine and one pooled lot (mixture of 6 individual lots).
Our results showed that these molecules had no significant
effects (either ion suppression or enhancement) on
quantification of phenobarbital, suggesting that their presence
is not a problem for quantifying phenobarbital for UDT.

Measured
Spiked
conc.
conc.
(ng/mL)
Stability
(ng/mL) Mean ± SD (%Recovery)
Freeze/thaw
(3 cycles)
Bench top
(6 h) at
room temp.
2 months at
-20 oC

Evaluation of analytical performance and robustness of our
FI-MS/MS method
Because our method does not use LC, it has a run time of only
2 min. This means that with our method, the throughput of one
MS/MS system can be as high as 720 samples per day, much
higher than the throughout achieved by any LC/MS/MS
method. Since the FI-MS/MS method developed is intended
for clinical use, it must be reliable and robust. In other words,
the performance of the method should not deteriorate after
several hundreds of injections and results should be
reproducible to avoid false positives and/or negatives, when
implemented in clinical toxicology labs for routine UDTs. As
demonstrated above, despite the presence of urine matrix,
our FI-MS/MS method could still accurately quantify
phenobarbital at 50 ng/mL (4 times lower than the cutoff
currently used in clinical labs) and the signal intensity of both
phenobarbital and IS was not compromised with the
elimination of LC. The key to our FI-MS/MS method is the
selection of proper fragmentation conditions and fragment
channels so that the effect of the matrix background can be
minimized. We have also tested the robustness of our

Low
High
Low
High

125
1600
125
1600

126.0 ±
1587.3 ±
125.2 ±
1590.7 ±

Low
High

125
1600

127.3 ± 0.5
1597.2 ± 2.3

0.6
4.3
0.42
5.43

100.7
98.5
100.4
99.4
101.8
99.8

Mixture of 6 lots, 10× dilution (n = 3)

FI-MS/MS method with over 1200 consecutive injections
during a 3-day period. It was found that the results were still
reproducible even after 1200 injections, demonstrating that
our method was robust enough for routine clinical operation.

CONCLUSIONS
We have successfully demonstrated the feasibility of using the
dilute-an-shoot FI-MS/MS method for quantification of
phenobarbital in urine. To the best of our knowledge, this is
the first ESI-MS/MS study to quantify phenobarbital without
LC separation. The method developed has the distinct
advantage of being able to quantify and detect the presence
of phenobarbital in urine even at 50 ng/mL. Importantly,

Table 2. Inter- and intra-assay accuracy and precision of phenobarbital in pooled blank human urine

Intra-assay

Low QC
Mid QC
High QC

Inter-assay

Spiked phenobarbital
conc. (ng ∕ mL)

Measured
mean ± SD
(ng/mL)

Precision
(%RSD)

Accuracy
(%RE)

Measured
mean ± SD
(ng∕ml)

Precision
(%RSD)

Accuracy
(%RE)

125
445
1600

122.03 ± 0.22
446.7 ± 1.07
1601.83 ± 2.56%

2.5
2.0
2.0

2.13
3.78
1.98

122.32 ± 0.37
446.88 ± 0.47
1598.83 ± 3.31

3.0
1.0
2.0

1.47
4.19
1.35

Mixture of 6 lots, 10× Dilution (n = 5)

the method is ultra-fast and robust with simple dilution for
sample pretreatment, short run time of 2 min, excluding HPLC
separation. The validation study has shown that this method is
accurate and precise, meeting the requirements of FDA
guidelines. We present a proof-of-concept that the application
of this method represents a robust, high-throughput and turn
key analytical platform to address emerging concerns of
analytical toxicological/clinical studies in urine. In spite of
the single drug analysis in this study, the results are highly
encouraging, and extending this approach to other drugs with
similar ionization patterns will be highly beneficial. This
method, an alternative approach to the current timeconsuming LC/MS/MS method, meets the requirement of
high-throughput UDT analysis with unparalleled speed. Its
compelling analytical features and versatility offer a major
improvement over existing methods. More importantly, the
FI-MS/MS approach can be a general method for fast analysis
of many other drug molecules present in clinical specimens.
Finally, our method was developed as a model system only
to test for the presence of phenobarbital in urine and the
application of this method to quantify other drugs needs
method validation for those drugs. Studies using this approach
to quantify other drug molecules are in progress in our lab.
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